- $2.95m
- -$5.59m
- $9.14m
U.S. STOCKS ON THE MOVE-Novavax, Cerence, Hibbett
Aravive rises as FDA grants fast-track tag for kidney cancer drug
Brief: Aravive Announces Fast Track Designation Of Batiraxcept For Treatment Of Ccrcc
Brief: Aravive Inc Files For Resale Of Up To 90.4 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Brief: Aravive Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-Coherent, Huntington Ingalls Industries, Spirit Aerosystems Holdings
Aravive Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aravive Reports Q3 2022 Financial Results
Brief: Biotechnology Value Fund L P Reports 6.4% Passive Stake In Aravive, Inc As Of October 27, 2022 - SEC Filing
Aravive Inc expected to post a loss of 62 cents a share - Earnings Preview
Drug developer Aravive gets $6 mln in milestone payment; shares up
Brief: Aravive Receives A $6 Mln Development Milestone Payment From Its Licensee
Brief: Aravive reports Q2 results
Brief: Aravive received notice from NASDAQ notifying that its common stock did not maintain minimum closing bid price
Brief: Aravive Appoints Rudy Howard As Chief Financial Officer
Brief: Aravive Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential Of Batiraxcept In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc)
Aravive Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP-First Solar, Henry Schein, Petiq
Brief: Aravive Inc Posts Qtrly Loss Per Share Of 62 Cents